Champions Oncology shares rise 8.16% intraday after AstraZeneca's CEO Pascal Soriot's ASCO faculty biography release.

Tuesday, Jun 3, 2025 3:14 pm ET1min read
Champions Oncology, Inc. rose 8.16% in intraday trading. The news event related to AstraZeneca, a company that Champions Oncology may have business relations with, did not directly impact the stock price.

Champions Oncology shares rise 8.16% intraday after AstraZeneca's CEO Pascal Soriot's ASCO faculty biography release.

Comments



Add a public comment...
No comments

No comments yet